Cybin Inc. (OTCMKTS:CYBN – Get Rating) – Oppenheimer dropped their Q3 2023 earnings per share estimates for shares of Cybin in a research report issued to clients and investors on Tuesday, November 15th. Oppenheimer analyst F. Brisebois now forecasts that the company will post earnings per share of ($0.08) for the quarter, down from their previous estimate of ($0.06). The consensus estimate for Cybin’s current full-year earnings is ($0.27) per share. Oppenheimer also issued estimates for Cybin’s Q4 2023 earnings at ($0.08) EPS and FY2023 earnings at ($0.29) EPS.
Cybin (OTCMKTS:CYBN – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.
Cybin Price Performance
Shares of Cybin stock opened at $0.44 on Friday. The stock has a market capitalization of $76.75 million, a price-to-earnings ratio of -1.61 and a beta of 1.35. The firm’s fifty day simple moving average is $0.55 and its 200-day simple moving average is $0.63. Cybin has a 12 month low of $0.39 and a 12 month high of $1.66.
Institutional Trading of Cybin
Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC increased its stake in shares of Cybin by 370.6% during the 1st quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock worth $61,000 after purchasing an additional 58,771 shares in the last quarter. Tcwp LLC purchased a new position in Cybin during the first quarter worth $55,000. Wedbush Securities Inc. purchased a new position in Cybin during the second quarter worth $40,000. IAG Wealth Partners LLC acquired a new position in shares of Cybin in the second quarter worth $47,000. Finally, Royal Bank of Canada lifted its position in shares of Cybin by 926.4% in the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock valued at $52,000 after acquiring an additional 98,596 shares in the last quarter. 8.78% of the stock is currently owned by hedge funds and other institutional investors.
Cybin Inc, a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation.
- Get a free copy of the StockNews.com research report on Cybin (CYBN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.